文献速递眼底病与葡萄膜炎眼整形与眼眶

兔模型显示动脉内化疗毒性为药物与剂量相关而非操作技术相关

Rabbit Model of Intra-Arterial Chemotherapy Toxicity Demonstrates Retinopathy and Vasculopathy Related to Drug and Dose, Not Procedure or Approach.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

该研究利用动脉内化疗(IAC)兔模型评估操作、药物、剂量和技术选择对眼结构和功能的影响。结果显示,生理盐水对照组无毒性,美法仑在0.4 mg/kg标准剂量下两种技术均未见血管/微血管异常,但0.8 mg/kg剂量下偶见严重微血管稀疏和小动脉闭塞,ERG下降呈剂量依赖性,卡铂引起眼部/眶周结构大量水肿。患者IAC偶见眶周肿胀/皮疹,仅在接受多次三联疗法的眼中间见视网膜病变或血管事件/出血,46%的IAC操作后出现短暂中性粒细胞减少,多在三联疗法后。结论认为IAC毒性主要与所用药物和剂量相关,而非IAC操作本身或所选技术。

要点

  • 兔模型中生理盐水对照组未见毒性,美法仑0.4 mg/kg标准剂量下两种技术均未见血管/微血管异常。
  • 美法仑0.8 mg/kg剂量下偶见严重微血管稀疏和小动脉闭塞,ERG下降呈剂量依赖性。
  • 卡铂引起眼部/眶周结构大量水肿,患者IAC后46%操作出现短暂中性粒细胞减少。

核心结论

  • IAC毒性主要与特定药物和剂量相关,而非IAC操作本身或所选技术。

研究设计与样本

  • 兔模型接受IAC美法仑(0.4-0.8 mg/kg)、卡铂(25-50 mg)或生理盐水,经直接眼动脉插管或模拟非闭塞技术给药。
  • 兔在IAC前及IAC后5至6周接受检查、ERG、眼底照相、荧光素血管造影、OCT和OCT血管成像评估眼结构和功能,每周获取血细胞计数。
  • 回顾性分析最近50例患者IAC治疗,评估眼部或全身并发症证据。

主要发现

  • 生理盐水对照组未见毒性。
  • 美法仑0.4 mg/kg标准剂量下,两种技术均未见血管/微血管异常。
  • 美法仑0.8 mg/kg剂量下偶见严重微血管稀疏和小动脉闭塞,ERG下降呈剂量依赖性。
  • 组织学显示美法仑剂量依赖性全视网膜层变性,地理上局限于血管密度最大区域。
  • 卡铂引起眼部/眶周结构大量水肿。

关键数值与推荐

  • 美法仑剂量0.4-0.8 mg/kg,卡铂剂量25-50 mg,生理盐水对照。
  • 兔IAC后5至6周评估眼结构和功能,每周获取血细胞计数。
  • 患者46%的IAC操作后出现短暂中性粒细胞减少,多在三联疗法后。

临床怎么用

  • IAC毒性应关注药物选择和剂量,而非操作技术本身。
  • 美法仑0.8 mg/kg剂量下需警惕微血管稀疏和小动脉闭塞风险。
  • 卡铂可能引起眼部/眶周大量水肿,需监测。
  • 三联疗法后需监测短暂中性粒细胞减少。

局限性

  • 兔模型结果需在患者中进一步验证。
  • 患者回顾性分析仅50例IAC治疗,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To use our intra-arterial chemotherapy (IAC) rabbit model to assess the impact of IAC procedure, drug, dose, and choice of technique on ocular structure and function, to study the nature and etiology of IAC toxicity, and to compare to observations in patients. METHODS: Rabbits received IAC melphalan (0.4-0.8 mg/kg), carboplatin (25-50 mg), or saline, either by direct ophthalmic artery cannulation, or with a technique emulating nonocclusion. Ocular structure/function were assessed with examination, electroretinography (ERG), fundus photography, fluorescein angiography, optical coherence tomography (OCT), and OCT angiography, prior to and 5 to 6 weeks after IAC. Blood counts were obtained weekly. We reviewed our last 50 IAC treatments in patients for evidence of ocular or systemic complications. RESULTS: No toxicity was seen in the saline control group. With standard (0.4 mg/kg) melphalan, no vascular/microvascular abnormalities were seen with either technique. However, severe microvascular pruning and arteriolar occlusions were seen occasionally at 0.8 mg/kg doses. ERG reductions were dose-dependent. Histology showed melphalan dose-dependent degeneration in all retinal layers, restricted geographically to areas of greatest vascular density. Carboplatin caused massive edema of ocular/periocular structures. IAC patients experienced occasional periocular swelling/rash, and only rarely experienced retinopathy or vascular events/hemorrhage in eyes treated multiple times with triple (melphalan/carboplatin/topotecan) therapy. Transient neutropenia occurred after 46% of IAC procedures, generally after triple therapy. CONCLUSIONS: IAC toxicity appears to be related to the specific drug being used and is dose-dependent, rather than related to the IAC procedure itself or the specific technique selected. These rabbit findings are corroborated by our clinical findings in patients.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Daniels AB, Froehler MT, Nunnally AH, et al. Rabbit Model of Intra-Arterial Chemotherapy Toxicity Demonstrates Retinopathy and Vasculopathy Related to Drug and Dose, Not Procedure or Approach. Invest Ophthalmol Vis Sci. 2019. PMID: 30882851. doi:10.1167/iovs.18-25346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。